Purpose: The response to sildena®l after radical retropubic prostatectomy (RRP) has been reported to be approximately 40% by the Sildena®l Study Group. We undertook a study in a large cohort of post-RRP erectile dysfunction (ED) patients in order to examine the relationship between satisfaction with sildena®l and time from surgery to start of sildena®l treatment. Methods: Pre-and post-operative erectile function was assessed by the O'Leary Brief Sexual Function Inventory questionnaire. Patient satisfaction with sildena®l before and after sildena®l treatment was assessed by the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire. Between April and October 1998, EDITS questionnaires were given to 579 patients who had undergone RRP between 1994 and 1998. 316 (55%) patients returned questionnaires. Of these, 198 (63%) had sildena®l treatment and completed post-treatment questionnaires and were included in the study group. Results: In the study group, mean age was 61y. Pre-operatively, 92% had erections suf®cient for vaginal penetration, 95% had bilateral nerve-sparing (NS) RRP. There was a signi®cant increase in the treatment satisfaction rate with increasing time from surgery. Between zero and six months after surgery, the treatment satisfaction rate was 26%, which improved with time, peaking at 60% between 18 months and 2y. Self-perceived erectile function as determined by post-RRP presildena®l treatment O'Leary questionnaires was not as predictive of response to sildena®l as time from surgery. Conclusions: The response to sildena®l appears to be dependent upon the interval between RRP and the start of sildena®l. The treatment satisfaction rate was found to peak at 60% between 18 months and 2y. Early nonresponders to sildena®l should not be disheartened, as they will more likely later respond.
Introduction
Some degree of erectile dysfunction (ED) is common in patients who have undergone radical prostatectomy. The incidence of ED following bilateral nervesparing radical retropubic prostatectomy (RRP) ranges from 24 ± 68% depending on the age of the patient, the length of time from surgery, the stage of the disease, co-existing morbidities, pre-operative sexual function, the nerve-sparing (NS) nature of the surgery, and the experience of the surgeon. 1 ± 4 Treatment modalities available to patients experiencing post-RRP ED include oral medications, vacuum constriction devices, transurethral delivery of prostaglandin E-1, intracavernous injections of vasoactive drugs, and penile prosthesis implantation. The clinical utility of these modalities is often diminished by their ineffectiveness or their invasive nature.
Sildena®l recently emerged as an effective oral treatment for ED of all causes. Penile erection is dependent on the relaxation of the corpora cavernosal smooth muscle and the penile vasculature. During sexual stimulation, cavernous nerves and endothelial cells release nitric oxide, which acts on guanylate cyclase to stimulate the production of cyclic guanosine monophosphate (cGMP), ultimately causing corporal smooth muscle and penile arteriolar relaxation. 5 ± 7 Sildena®l acts by selectively inhibiting cGMP-speci®c phosphodiesterase type 5, which is the major isozyme metabolizing cGMP in the corpus cavernosum. 8 The Sildena®l Study Group reported that in a double-blind, placebo-controlled dose-escalation study of impotent patients, 69% of all attempts at sexual intercourse were successful in the sildena®l group. 9 However, these investigators reported only a 43% ef®cacy in a subgroup analysis of 142 patients with ED after RRP. 10 No mention was made of the nature of the surgery, the stage of disease, or time from surgery. A recent study by Zippe et al 11 speci®cally assessed the ef®cacy of sildena®l in a small group of post-RRP patients, reporting that 80% (12 of 15) of patients who underwent a bilateral nerve-sparing procedure and 0% (0 of 3) of patients who underwent a unilateral nerve-sparing procedure were able to have erections suf®cient for penetration. No strati®cation as to time from surgery was reported.
As there is a time-dependent improvement in natural erectile function after RRP without intervention, the timing of sildena®l treatment may be a possible factor in its ef®cacy. 3 No previous studies have speci®cally looked at the ef®cacy of sildena®l treatment in post-RRP patients as a function of time from surgery.
Traditionally, urologists have waited for one year or more after RRP to initiate interventions for ED. A study by Montorsi et al 12 suggested that intervention with penile injections within the ®rst postoperative year could lead to an increase in the recovery rate of spontaneous erections.
We undertook a study to evaluate the ef®cacy of sildena®l treatment in a large cohort of ED patients treated with sildena®l at different time points after RRP, in order to determine whether ef®cacy was in¯uenced by the time from surgery that sildena®l treatment was started.
Materials and methods
579 patients underwent RRP by one surgeon (HL) between 1994 and 1998. Sildena®l was approved by the FDA on 27 March, 1998. The FDA approval of sildena®l provided us with a unique opportunity to study a large population of men after NSRRP who had not previously taken sildena®l, i.e.,`Viagra naõ Ève'. All of the men who underwent RRP received in person or by mail, post-sildena®l treatment Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaires (Table 1) between April and October 1998. EDITS is the only statistically validated and reliable, self-administered questionnaire designed to evaluate the effectiveness of non-surgical treatments for male ED, including sildena®l. 13, 14 316 (55%) patients returned the questionnaires. Of these, 198 (63%) had experienced sildena®l treatment and completed posttreatment questionnaires.
Pre-sildena®l treatment EDITS questionnaires were available in 80 of the 198 patients. A majority of the 80 patients had been treated with other treatment modalities (intracavernosal therapy, intraurethral prostaglandin, or vacuum device) under the care of AM and HL. These same patients were instructed to take 50 mg of sildena®l q.h.s. and p.r.n., one hour prior to intercourse. The remaining 118 patients, who did not complete pre-treatment EDITS questionnaires, had been treated elsewhere with sildena®l 50 or 100 mg, on a p.r.n. basis.
We assessed ef®cacy by examining the responses to questions 1 and 2 of the 11-question EDITS, which refer to overall satisfaction with treatment and self-assessment of how sildena®l met their During the past four weeks, how satis®ed have you been with how quickly the treatment works? (Very satis®ed, somewhat satis®ed, neither satis®ed nor dissatis®ed, somewhat dissatis®ed, very dissatis®ed) 6. During the past four weeks, how satis®ed have you been with how long the treatment lasts? (Very satis®ed, somewhat satis®ed, neither satis®ed nor dissatis®ed, somewhat dissatis®ed, very dissatis®ed) 7. How con®dent has this treatment made you feel about your ability to engage in sexual activity? (Very con®dent, somewhat con®dent, it has had no impact, somewhat less con®dent, very much less con®dent) 8. Overall, how satis®ed do you believe your partner is with the effects of this treatment? (Very satis®ed, somewhat satis®ed, neither satis®ed nor dissatis®ed, somewhat dissatis®ed, very dissatis®ed) 9. How does your partner feel about your continuing to use this treatment? (My partner absolutely wants me to continue, prefers me to continue, has no opinion, prefers me to stop, absolutely wants me to stop) 10. How natural did the process of achieving an erection feel when you used this treatment over the past four weeks? (Very natural, somewhat natural, neither natural nor unnatural, somewhat unnatural, very unnatural) 11. Compared to before you had an erection problem, how would you rate the naturalness of your erection when you used this treatment over the past four weeks in terms of hardness? (A lot harder than before I had an erection problem, somewhat harder than before I had an erection problem, the same hardness than before I had an erection problem, somewhat less hard than before I had an erection problem, a lot less hard than before I had an erection problem)
Patient satisfaction with sildena®l EK Hong et al expectations, respectively. The responses to questions 1 and 2 were rated on a scale of 1 (very satis®ed) to 5 (very dissatis®ed). Satisfaction with sildena®l was also assessed by the other domains of the EDITS questionnaire. Pre-and post-RRP sexual function was assessed by the responses to four of the domains of the 11-question validated, reliable O'Leary Brief Sexual Function Inventory (OBSFI) questionnaire: sexual drive, erectile function, erectile function problem assessment, and overall satisfaction ( Table 2) . 15 As the OBSFI was not available before November 1995 and not all patients received their ED treatment at our institution, pre-and post-RRP OBSFI questionnaires were available in 70 of 198 patients who had completed post-sildena®l treatment EDITS questionnaires.
The surgeon's pre-operative history documented pre-operative erectile function and intercourse frequency. The type of RRP, bilateral nerve-sparing, unilateral nerve-sparing, or non-nerve-sparing, was determined by chart review of the operative note. Pathological stage was determined by chart review of the pathology report. Time after surgery to start of sildena®l treatment was determined by a question added to the EDITS questionnaire or by chart review.
Statistical analysis was performed using the JMP statistical software program version 3.2.2 developed by the SAS Institute. All statistically signi®cant changes represent differences with P`0.05 using the paired t-test.
Results
Background data of total population examined 579 patients who underwent RRP received the EDITS questionnaire. 316 (55%) returned the questionnaire. There was no signi®cant difference in mean age, pathological stage, and mean time from surgery to the date of the study (November 1998) between the patients who returned questionnaires and those who did not.
Background data of patients who returned questionnaires
Of the 316 patients who returned questionnaires, 198 (63%) had experienced sildena®l and completed the post-treatment questionnaire. The group of men (118) who did not experience sildena®l was older by 1.7 y, were four months farther out from surgery, but were of similar pathological stage. The reasons for not taking sildena®l are shown in Table 3 .
Background data of study group and of subgroups strati®ed by time from surgery 198 patients who experienced sildena®l and completed post-treatment EDITS questionnaires were included in the study group. Mean age at the time of the study was 60.7 y. 92% had pre-operative The study group was strati®ed into ®ve subgroups according to time from surgery to start of sildena®l treatment: 0 ± 6 months (n 53), 6 ± 12 months (n 42), 12 ± 18 months (n 34), 18 ± 24 months (n 25), and b 24 months (n 44). Subgroup analysis of background data revealed no signi®cant differences between the subgroups in pre-operative erectile function (as determined by surgeon's assessment), intercourse frequency, nerve-sparing nature of RRP, and pathologic stage. The only difference was that the subgroups with patients who started sildena®l farther out from surgery had a greater mean age.
The patients for whom pre-and post-RRP OBSFI questionnaires were available (n 73) had a mean age of 59.3 y. The extent of post-operative presildena®l treatment ED is documented in Table 4 . Pre-and post-operative changes in the domains of erectile function, erectile function problem assessment, and overall patient satisfaction with sex life achieved statistically signi®cant differences. Preand post-operative changes in the sex drive domain did not achieve a statistically signi®cant difference. In addition, patients with post-operative OBSFI erectile function domain scores of zero did not respond as well to sildena®l as patients with scores of one or greater (P`0.0013) ( Table 5) .
Pre-and post-sildena®l treatment EDITS scores strati®ed by time from surgery
We compared pre-treatment and post-treatment EDITS scores on the 80 men who completed both pre-and post-treatment questionnaires. At six months, although there was no statistical improvement in any of the domains, both the patients and their partners wanted to continue the treatment. After 24 months, a statistically signi®cant difference was achieved in all questions except in the domains of speed of onset action, con®dence in engaging in sexual activity, and partner satisfaction (Table 6 ).
Subgroup analysis revealed that it took 18 months before the differences between pre-treatment and posttreatment EDITS score achieved consistent signi®cant differences in a majority of the domains. These trends are consistent with those of the entire study group.
Satisfaction rates after sildena®l treatment in the study group and in subgroups strati®ed by time from surgery Overall, 41% of patients were very or somewhat satis®ed with sildena®l treatment, 30% felt that sildena®l treatment completely or considerably met their expectations, 73% were very or moderately likely to continue using sildena®l, 91% found sildena®l easy to use, 42% were satis®ed with the speed of onset, 39% were satis®ed with duration of action, 43% felt more con®dent about engaging in sexual activity, 39% felt that their partner was satis®ed, 66% felt that their partner wanted to Patient satisfaction with sildena®l EK Hong et al continue treatment, 53% felt that their erections were more natural, and 17% felt that their erections were harder than before the onset of ED. Subgroup analysis revealed a signi®cant increase in patient satisfaction rate with increasing time from surgery (Table 7) Between zero and six months, 23% of patients were satis®ed with treatment with a steady improvement to a peak of 60% between 18 months and 2 y. The difference in satisfaction percentage rates between Group A (0 ± 6 months) and the later time groups achieved statistical signi®cance after 12 months in four out of ®ve domains measuring ef®cacy (Table  8 ). Similar trends with increasing time from surgery were seen in the domains of meeting expectations, instillation of con®dence, partner satisfaction, speed of onset, duration of action, and naturalness of erections (Figures 1.2, 1.3, 1.4, 2.2, 2.3, and 2.4 ). High positive rates were seen in all time-groups in the domains of ease of use, patient treatment continuation, and partner treatment continuation (Figures 2.1, 3.1, and 3.2) . In these domains, there was little change between time groups. Low positive rates were seen in all time-groups of the domain comparing ®rmness of erections to before the onset of ED (Figure 1.5) .
Discussion
This is the largest and most comprehensive reported study of the effectiveness of sildena®l in`Viagra Table 6 Difference between pre-and post-sildena®l treatment EDITS scores Interval since RRP EDITS question 0 ± 6 months 6 ± 12 months 12 ± 18 months 18 ± 24 months b 24 months
± ± ± ± * statistically signi®cant, ± not statistically signi®cant. Table 7 Percentage of patients with post-sildena®l treatment EDITS scores of 1 or 2 (very or somewhat satis®ed)
Interval since RRP 10  30  50  75  64  63  11  13  5  27  17 27 Table 8 The difference in satisfaction percentage rates between Group A (0-6 months) and later time groups
EDITS question
Interval since RRP EDITS question 6 ± 12 months 12 ± 18 months 18 ± 24 months b 24 months
* statistically signi®cant, ± not statistically signi®cant.
Patient satisfaction with sildena®l EK Hong et al naõ Ève' patients following RRP. The effectiveness of sildena®l in the patients following RRP has been reported to be between 43% and 80%. 9, 11 Theoretically, one would expect sildena®l to work in patients where there was suf®cient neurotransmission to release an adequate amount of NO to cause penile smooth muscle and arteriolar relaxation. Therefore, it is not surprising that sildena®l is ineffective following non-nerve-sparing RRP as reported by Zippe et al. 11 No studies to date have investigated whether the response to sildena®l is time-dependent after NSRRP. The etiology of ED after NSRRP has been attributed to psychogenic, vascular, veno-occlusive, or nerve injury, either permanent or temporary. Evidence of a psychogenic cause is not supported by Rigiscan studies. 16 Arterial etiologies are weakly supported in the literature, while venous leak is increasingly recognized as a possible cause, whether from chronic cavernosal hypoxia or smooth muscle ®brosis. 17 The most likely etiology is neurogenic injury, either partial or complete. Recovery of function after NSRRP takes time. The reason has not been clearly explained, but it is reasonable to assume that there is a variable period of neurapraxia. If there is nerve function that is recovering with time, sildena®l should become more effective with increasing time from surgery, assuming that there is no irreversible end organ damage. We undertook this study to evaluate the effectiveness of sildena®l in a large cohort of`single surgeon' RRP patients, in order to eliminate differences in surgical technique and operative indications. By using this cohort, we hoped to have as homogeneous a patient population as possible. We had access to extensive patient data, including patient demographics, pre-operative sexual function, operative information, and post-operative sexual function. The extent of normal pre-operative erectile function and abnormal post-operative erectile function is clearly demonstrated in the OBFSI with a 10-fold decrease.
We had a suf®cient number of cases in each sixmonth time period to assess time-dependent effectiveness in all the domains of the EDITS questionnaire. Our ®nding that over time men became more responsive to sildena®l is consistent with the concept that the nerves are regenerating or recovering from the trauma of the surgery. Between 18 and 24 months, 60% of men were very or somewhat satis®ed. These patients had post-op libido comparable to their pre-op state as measured by the sex drive domain of the OBSFI, eliminating lack of sex drive as a reason for the ED. The only baseline difference between the six-month cohort groups was their age. This is predictable, as the last group is roughly two years older than the ®rst six-month cohort group. Within the ®rst and last age-groups, there were no other signi®cant demographic differences. There appeared to be less recruitment of`new responders' after 24 months (Figure 1.1) . The Patient satisfaction with sildena®l EK Hong et al decreasing perceived effectiveness may be from end organ damage from lack of erections for two years or from disillusionment and frustration with longstanding erectile failure.
It appeared that during the ®rst 12 months, patients were dissatis®ed with sildena®l and did not feel that it met their expectations. Nonetheless, they and their partners were still inclined to continue using the medication. It is during this time period that patients should consider pursuing aggressive injection therapy, or`sexual rehabilitation' as described by Montorsi et al. 12 From a neuromuscular standpoint, to ignore the end organ after a nerve injury makes little sense.
The optimal dosing frequency of sildena®l remains to be determined. In our study it varied between the patients who were treated in our of®ce (80) and the patients treated by outside urologists (118). Most patients did not start sildena®l before three months from surgery. The patients in our of®ce took sildena®l nightly, starting at a dose of 50 mg a night and escalating to 100 mg, if 50 mg was ineffective. The reason for the nightly sildena®l was to try to capture any nocturnal activity and to potentiate any nocturnal erections. We thought that nightly sildena®l was less frustrating to the patient who would not be faced with the disappointment of repeated failed sexual attempts. Patients treated elsewhere received p.r.n. dosing of sildena®l. Comparing the`every night' sildena®l group to the p.r.n. group, there was a statistically signi®cant improvement in treatment satisfaction rate as measured by EDITS question 1, with no other demographic differences (P`0.01). Though one might argue that our patients were more motivated because they sought treatment, it is conceivable that the ampli®cation of nocturnal erections resulted in a better experience with sexual intercourse.
The EDITS does not directly address whether the erections were suf®cient for penetration. Question 11 of EDITS speci®cally questions the quality of the erection as compared to prior to surgery. The improvement in this domain did not achieve statistical signi®cance with increasing time from surgery. As 95% of the men had normal preoperative erectile function, their expectations were perhaps high. Nonetheless, 27% of patients described their post-operative erections after 24 months as harder than they had before surgery.
Although this study is retrospective and does not have a placebo arm, there is a de®nite implication that sildena®l becomes increasingly effective over time. Longitudinal prospective studies will be required to validate these ®ndings.
Conclusions
The response to sildena®l appears to be dependent upon the interval between RRP and the administration of the drug. Men following NSRRP who were previously potent had an overall satisfaction rate of 60% when sildena®l was administered between 18 and 24 months after surgery. On the other hand, men in the 0 ± 6 month time-group cannot be expected to respond satisfactorily to p.r.n. sildena®l and should be encouraged to try injection or vacuum therapy. Early failure to sildena®l does not necessarily imply lack of ef®cacy in the future, and patients should be encouraged to continue trying sildena®l at regular intervals. It remains to be determined whether earlier treatment with sildena®l will result in more rapid and higher degree of return of function after NSRRP.
